|
| Tuesday, October 22, 2024 |
|
|
雲頂新耀宣佈耐賦康®NefIgArd III期全球臨床試驗完整中國亞組資料的積極結果 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈《腎臟360》（Kidney 360）雜誌以「Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results」《耐賦康®在中國大陸IgA腎病患者中的療效和安全性：2年NefIgArd試驗結果》為題，刊登了耐賦康®（布地奈德腸溶膠囊，NEFECON®）在NefIgArd III期研究中完整2年資料的中國亞組資料。 more info >> |
|
|
云顶新耀宣布耐赋康(R) NefIgArd III期全球临床试验完整中国亚组数据的积极结果 |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布《肾脏360》（Kidney 360）杂志以"Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results"《耐赋康 在中国大陆IgA肾病患者中的疗效和安全性：2年NefIgArd试验结果》为题，刊登了耐赋康®（布地奈德肠溶胶囊，NEFECON® 在NefIgArd III期研究中完整2年数据的中国亚组数据。 more info >> |
|
| Monday, October 21, 2024 |
|
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1". There are no restrictions on initial proteinuria levels in the approved indication. more info >> |
|
|
云顶新耀宣布中国台湾地区药政部门批准全球首个对因治疗IgA肾病药物耐赋康®的新药上市许可申请 |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布，中国台湾地区药政部门（TFDA）已批准耐赋康®（布地奈德肠溶胶囊，NEFECON®）用于治疗罹患原发性免疫球蛋白A肾病变(IgA nephropathy)且病情有进展风险的成人病人，用以延缓肾功能下降1 ，且无基线蛋白尿水平限制。 more info >> |
|
|
雲頂新耀宣佈中國台灣地區藥政部門批准全球首個對因治療IgA腎病藥物耐賦康®的新藥上市許可申請 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈，中國台灣地區藥政部門（TFDA）已批准耐賦康®（布地奈德腸溶膠囊，NEFECON®）用於治療罹患原發性免疫球蛋白A腎病變(IgA nephropathy)且病情有惡化風險的成人病人，用以減緩腎功能下降1，且無基線蛋白尿水平限製。 more info >> |
|
| Friday, October 18, 2024 |
|
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery |
| Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks. more info >> |
|
|
云顶新耀股价升两成 盈利潜力助力估值修复 |
| 云顶新耀(1952.HK)今日收盘升20.46%，最高触及28.6港元，公司自公布中期业绩开始股价一路向好，今日成交额达2.91亿元。消息层面看到，交银国际发表报告称，予内地医药行业“领先”评级，其中重点推荐了云顶新耀等一众股票。 more info >> |
|
|
雲頂新耀股價升兩成 盈利潛力助力估值修復 |
| 雲頂新耀(1952.HK)今日收盤升20.46%，最高觸及28.6港元，公司自公佈中期業績開始股價一路向好，今日成交額達2.91億元。消息層面看到，交銀國際發表報告稱，予內地醫藥行業「領先」評級，其中重點推薦了雲頂新耀等一眾股票。 more info >> |
|
| Thursday, October 3, 2024 |
|
|
云顶新耀耐赋康®入选《2024版KDIGO指南草案》，中期业绩强劲增长，展现行业领军地位 |
| 近日，云顶新耀再度传来利好消息，其核心产品耐赋康®（布地奈德肠溶胶囊，NEFECON®）作为唯一的对因治疗药物，被纳入《2024版KDIGO IgA肾病和IgA血管炎临床管理实践指南（公开审查草案）》(以下简称"新版指南（草案）")，推荐有疾病进展风险的IgA肾病患者进行9个月的耐赋康®治疗（2B）。 more info >> |
|
| Wednesday, October 2, 2024 |
|
|
NEFECON Included in 2024 KDIGO Clinical Practice Guidelines |
| Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). more info >> |
|
|
|
|
